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INTRODUCTION
In 1999, the NIH Recombinant DNA
Advisory Committee held a Gene Therapy
Policy Conference on in utero gene transfer
(NIH, 1999) and determined that it would
be premature to undertake in utero gene
transfer research in humans (RAC, 1999).
Much has happened since then. Gene
transfer research enrolling infants and very
young children as patient-subjects has had
results both beneficial and harmful in sev-
eral conditions (Hacein-Bey-Abina et al.,
2003; Aiuti et al., 2012; Corrigan-Curay
et al., 2012). Some fetal surgical interven-
tions have become accepted (Adzick et al.,
2011). And much has been learned about
the immune system and how pregnancy
influences immune response.
We now know a lot more about how
much more there is to learn. Researchers
in cell- and gene-based interventions are
eager to move to human trials in order
to continue the learning process. Yet fun-
ders and oversight bodies are reluctant to
support cell-based intervention research in
human fetuses. In this commentary we
address probable reasons for this hesi-
tancy, reasons to move forward with cau-
tion, and issues to address in planning
first-in-human (FIH) trials of cell-based
interventions in utero.
REASONS FOR RELUCTANCE
First, there is concern that existing alter-
natives obviate the need for in utero
interventions—that is, if in utero treat-
ments are unnecessary, then in utero
research is too. For couples known
to be at risk of giving birth to off-
spring with serious genetic or metabolic
anomalies, in vitro fertilization (IVF) and
preimplantation genetic diagnosis (PGD)
are available (Dresser, 2004). For couples
without known risk factors, prenatal diag-
nosis and abortion are available. However,
IVF and PGD are costly, burdensome, and
thus unavailable for many couples, and
abortion is morally unacceptable to many
and increasingly difficult to obtain for
many others. Thus, these alternatives by
no means eliminate the need for or the
value of in utero interventions, and cannot
justify failure to support in utero research
(Strong, 2011).
Second, the growing tendency to cat-
egorize unprecedented and untested stem
cell interventions as innovation rather
than research may be thought to offer
investigators an alternate route to the
clinic. However, the extensive cautionary
literature on the problem of innova-
tion makes clear that FIH in utero cell-
based interventions should be regarded
and treated as research (Chescheir and
Socol, 2005; Hyun et al., 2008; Daley, 2012;
Sugarman, 2012).
Finally, and most important, federal
regulations restrict research involving
pregnant women and fetuses. 45 CFR
46.204, in Subpart B, requires prior “scien-
tifically appropriate preclinical and clinical
studies” and permits only trials in which
“[t]he risk to the fetus is caused solely
by interventions or procedures that hold
out the prospect of direct benefit for the
woman or the fetus; or, if there is no such
prospect of benefit, the risk to the fetus
is not greater than minimal and the pur-
pose of the research is the development of
important biomedical knowledge which
cannot be obtained by any other means”
and “[a]ny risk is the least possible for
achieving the objectives of the research”
(DHHS, 2014a).
Satisfying these regulatory require-
ments means successfully addressing
three definitional controversies in research
ethics. The first is about what constitutes
good prior research and persuasive data.
The regulations assume that clinical stud-
ies in adults and children will precede
research on pregnant women and fetuses,
and that the resulting data will help to
establish potential benefit and minimize
risks of harm. This is the traditional model
for pharmaceutical research. However,
the translational research trajectory for
novel biotechnologies has rarely applied
that model, in large part because better
data can often be obtained from younger
patient-subjects, and older patients may
not be suitable subjects.
Another definitional difficulty lies in
defining minimal risk. The obligation to
pursue studies that pose no more than
minimal risk in the absence of poten-
tial direct benefit raises important ques-
tions about when risk can be considered
minimal. The federal regulations define
minimal risk in terms of daily life and rou-
tine tests and procedures (DHHS, 2014c).
What are the daily life risks of fetuses and
pregnant women? Should the risks of pro-
cedures like amniocentesis be considered
in assessing risk (Iltis, 2011)?
Third, there is disagreement about
when it is appropriate to regard a study
as offering potential benefit. Wishful
thinking notwithstanding, the prospect
of direct benefit cannot reliably be held
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out to patient-subjects in FIH trials. The
focus of FIH research must therefore be
on minimizing the risks of harm. Yet
both research enrolling children under
Subpart D (DHHS, 2014b) and research
enrolling pregnant women and fetuses
under Subpart B pose a significant risk
of the therapeutic misconception, whereby
potential subjects, investigators, funding
agencies, themedia, and research oversight
bodies tend to view research as treatment,
exaggerate the potential for benefit, and
underestimate the risks of harm (Dresser,
2002; Henderson et al., 2005).
A related problem in research with
pregnant women, fetuses, and children
is “benefit creep,” whereby investigators
and IRBs exaggerate the prospect of direct
benefit in order to meet the regulatory
requirements for enrolling children and
fetuses as patient-subjects (King, 2000).
Unfortunately, overstating the potential
for direct benefit in FIH research can easily
both create the therapeutic misconception
and end with the materialization of serious
and unexpected risks of harm.
Addressing these challenges and mak-
ing the argument that the time is right
for FIH trials in pregnant women and
fetuses is thus no easy feat. It requires clear
and significant justification and persuasive
data, and may be quite challenging under
the current regulatory scheme.
REASONS TO PROCEED (WITH
CAUTION)
Nonetheless, there are good reasons to
move forward toward FIH trials of cell-
based interventions in utero. First, animal
models and other types of preclinical mod-
eling have advanced considerably in the
last 15 years and continue to improve.
Thus, it is becoming easier to assemble sci-
entifically relevant preclinical data, even
when clinical data from adult patient-
subjects is unavailable or uninformative
(Chescheir and Socol, 2005; Coutelle and
Ashcroft, 2012).
Second, the effects of early inter-
ventions may be easier to measure in
treatment-naive patient-subjects, making
it more feasible to demonstrate proof of
concept in FIH studies (King and Cohen-
Haguenauer, 2008). Thus, very young
patient-subjects may bemore likely to pro-
vide data demonstrating proof of principle
or even surrogate measures suggestive of
efficacy. In addition, in some disorders,
earlier interventions may be more effec-
tive. Characteristics of the immune system
in fetuses, their size, and the opportu-
nity to intervene at an earlier stage of ill-
ness all may help increase the effects of
cell- and gene-based interventions, though
much remains unknown (Niyibizi and Li,
2009; Strong, 2011).
Finally, as has been demonstrated in
preclinical and clinical research for a range
of conditions and interventions (see the
rest of this issue), cell-based FIH trials
in uterowill surely have another important
outcome that is too often overlooked in
the pressure to achieve clinical translation:
Simply learning more about the com-
plex immune relationship between preg-
nant woman and fetus. Despite profound
societal desire for progress in treatment
of specific diseases and conditions, trans-
lational research often yields important
knowledge when it proceeds in unantici-
pated directions. As much (or more) can
be learned from going sideways, or back to
basics, as from pushing toward the clinic
(Kimmelman, 2010).
MOVING TO HUMANS: QUESTIONS TO
CONSIDER
It is therefore time to restart progress
toward FIH trials in cell- and gene-based
in utero interventions. When considering
FIH trials, the following questions must be
addressed:
• Has enough preclinical information
been collected so that the only reason-
able way to learn more is to move to
humans?
• Has enough been done to reduce the
risks of harm to humans, and to max-
imize the likelihood that the interven-
tion will ultimately show benefit in
humans?
• Has the point of irreducible uncertainty
been reached?
• Is the amount of irreducible uncertainty
small enough that it is fair to subjects to
ask them to participate?
Affirmative answers, supported with rea-
soning and data, can provide both justifi-
cation for moving to human trials and the
basis for informed decision-making about
participation. However, answering these
questions is challenging for FIH in utero
research. Following are several specific
considerations for FIH in utero research
that suggest the benefit of reconsidering
Subpart B.
First, couples who have undertaken IVF
and PGDmay be willing to donate affected
embryos for research rather than discard-
ing them (Lyerly and Faden, 2007), and
couples who have learned that their fetus
is affected may be willing to participate
in research prior to obtaining an abor-
tion. It will be necessary to design tri-
als to make fair and appropriate use of
these subject populations (Dresser, 2004;
Chervenak andMcCullough, 2007; Strong,
2011; Coutelle and Ashcroft, 2012).
Second, to support informed decision-
making about trial participation, clear and
complete information must be provided
about the risks of harm to both sub-
jects, the unlikely prospect of direct benefit
to the fetus, alternatives to participation,
requirements for long-term follow-up, and
the future possibility of autopsy. It must be
emphasized that FIH trials represent proof
of concept studies and are not designed or
expected to offer direct benefit to the fetus
(NIH, 1999; King, 2000; Dresser, 2004;
King et al., 2005).
Although direct benefit is unlikely, the
consequences of partial success should be
addressed whenever relevant. If correc-
tion were to be partial, would that be a
success—that is, better than no correction
because it can be augmented by available
treatments? Or would it be a failure—that
is, worse because it promises impaired sur-
vival (NIH, 1999; Chescheir and Socol,
2005)? There are no easy answers to these
questions; nonetheless, investigators must
prepare to address them.
Third, important choices must be made
about where to start—with what dis-
eases and conditions—in these FIH tri-
als. Concentrating effort where the need
is greatest, where the most progress has
already been made, and where funding
is available are very different starting
points (NIH, 1999; Dresser, 2001; King
and Cohen-Haguenauer, 2008).
Finally, it is essential to consider
whether there are appropriate ways to
minimize the risks of harm and/or increase
the prospect of direct benefit in FIH
in utero research. Harm-benefit assessment
must be detailed, and should distinguish
between direct health benefits from the
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experimental intervention and benefits to
patient-subjects that arise from participat-
ing in research generally (such as the sat-
isfaction of trying everything or the value
of altruism), not from the intervention
itself (King, 2000). The question is not
only about what risks of harm and poten-
tial benefits exist, but also about how we
measure, judge, and compare them (Iltis,
2011).
Some researchers have argued that it is
unethical to conduct phase I gene trans-
fer studies in any patient-subjects because
there is no prospect of direct benefit.
Instead, they argue, studies should begin
at the phase II/III stage (Coutelle and
Ashcroft, 2012). This argument appears to
assume that an FIH trial of an in utero
intervention would be justified if it were
designed to provide doses calculated or
expected to be therapeutic. This is a per-
fect example of unacceptable and poten-
tially unsafe “benefit creep.” No matter
how the study is designed and what data
precede it, someone has to be first, and
what researchers believe will be safe and
effective often fails to realize those hopes.
CONCLUSION
The benefit creep problem demonstrates
the need to address the growing lack of
fit between regulatory requirements for
research with pregnant women, fetuses,
and children and the realities of FIH
and other early-stage research involv-
ing novel biotechnologies. Reconsidering
Subpart B need not mean exposing vul-
nerable patient-subjects to excessive risk.
FIH in utero cell- and gene-based inter-
vention trials should require highly per-
suasive preclinical data, and the amount
of irreducible uncertainty should be well-
justified, but a prospect of direct ben-
efit should not be required. Instead,
researchers must do their best to iden-
tify and minimize all risks of harm, and
provide clear and complete information
to potential subjects. Then, if a well-
informed pregnant couple views partic-
ipation in the research as a reasonable
choice, even if one of their reasons is “try-
ing everything just in case,” it may be time
to move forward.
This step must be taken deliberately,
with thorough oversight, care for patient-
subjects, and respect for what we do
and do not know. Ongoing public and
professional discussion is essential, as best
practices for the design, conduct, and over-
sight of in utero research continue to
evolve.
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